Patients and families

Healthcare Professionals (HCPs)

About us

Contact
Country websites

Attention

For UK healthcare professionals (Nephrologists/Renal Nurses and Pharmacists) information only on Fresenius Medical Care’s medicines, medical devices, services, educational resources and more.

I'm a UK healthcare professional

Important notice – this site is intended for UK healthcare professionals only. By entering this site, and clicking on the button “Accepted and Confirmed”, you are confirming that you are a UK healthcare professional. In addition to educational resources, this site contains promotional information.

UK/HEMA/FME/0922/0005 Date of Preparation: November 2022

Back to the homepage Accepted and confirmed

Immunoadsorption

Treatment of autoimmune diseases

Treatment of autoimmune diseases

DISCLAIMER

The product labels depicted may differ due to regulatory adaptations and changes in the legal form of the legal manufacturer.

Antibodies

Antibodies or autoantibodies often play a key role in solid organ transplantation and in autoimmune disorders. This is frequently associated with the activation or agonistic stimulation of cell-surface mechanisms (e.g. complement factors) or with antagonistic blockage of certain receptors. Immunoadsorption therapy removes antibodies or immune complexes from the blood plasma. Due to its selectivity, it can treat a wide range of autoantibody mediated clinical indications.1

During immunoadsorption, the targeted antibody classes are largely removed through strong binding affinity to different ligands of the adsorber matrix. This can alleviate the symptoms of disease, including in the acute state, and possibly prevent the disease’s progression.

GLOBAFFIN
Effective broad-spectrum immunoadsorption2,3

A number of serious diseases have an autoimmune pathophysiology and are sometimes difficult to treat, particularly when a quick and efficient elimination of autoantibodies is needed.

GLOBAFFIN

The GLOBAFFIN column is intended for the removal of immunoglobulins from the plasma of patients with specific autoantibodies associated with their disease.4

Treatment with GLOBAFFIN is characterized by:

  • Immunoadsorber with synthetic peptide ligand (peptide-GAM146)2
  • Twin adsorber system with multiple-use and multiple-pass characteristics. Generally, 1.5 to 2.5-fold of the patient’s plasma volume may be perfused through one pair of columns during a single treatment session4
  • Semi-selective and efficient removal of IgG immunoglobulines5

 

Nephrology
Dermatology
Neurology

Related content

No Results Found
PREVIOUS
    NEXT

    1 Hamilton P et al. 2019, chapter 4 in Karkar A (ed.), Aspects in Continuous Renal Replacement Therapy. IntechOpen, London

    2 Rönspeck W et al. Ther Apher Dial 2003; 7(1):91-97

    3 Fuchs K et al. Ther Apher Dial 2022; 26:229-241

    4 Instructions for Use GLOBAFFIN, Ref. 35840034/5

    5 Biesenbach P et al. Atheroscler Suppl 2009; 10(5):114-121

    Contact
    Country websites

    All contact information

    Social Media

    UK/HEMA/FME/1022/0001 Date Of Preparation: October 2022 © Fresenius Medical Care UK Ltd 2025

    Privacy policy

    Cookie settings

    Imprint